Related Experiment Video
Updated: May 9, 2026
08:50
Thrombus Profiling Assay: A Microfluidics-Based Platform for Comprehensively Characterizing Biomechanical Thrombogenesis
Published on: January 9, 2026
Thrombocytosis: Rapid Evidence Review
Pamela M Williams1, Alan L Williams2
1Department of Family Medicine at the Uniformed Services University of the Health Sciences, Bethesda, Maryland.
American Family Physician
|May 8, 2026
Summary
Thrombocytosis, a high platelet count, is often secondary but can indicate essential thrombocythemia, a myeloproliferative neoplasm. Diagnosis involves genetic testing and risk stratification for managing thrombosis risk.
Area of Science:
- Hematology
- Oncology
Background:
- Thrombocytosis is defined as a platelet count ≥ 450 × 103/μL.
- While often secondary, persistent thrombocytosis may signal myeloproliferative neoplasms like essential thrombocythemia (ET).
- ET presents with symptoms such as headaches, paresthesia, erythromelalgia, splenomegaly, thrombosis, or hemorrhage.
Purpose of the Study:
- To outline the diagnostic approach for persistent thrombocytosis.
- To detail the workup for suspected essential thrombocythemia.
- To guide risk stratification and management of ET.
Main Methods:
- Confirming thrombocytosis with repeat CBC and peripheral smear.
- Performing JAK2, CALR, and MPN gene variant testing.
- Utilizing the International Prognostic Score for Thrombosis (IPSET) for risk stratification.
- Considering bone marrow biopsy if ET is suspected and genetic testing is negative.
Main Results:
- Diagnostic workup includes genetic testing (JAK2, CALR, MPN) and risk assessment using the revised International Prognostic Score of Thrombosis for Essential Thrombocythemia (IPSET).
- Management strategies involve addressing cardiovascular risk factors, low-dose aspirin, and cytoreductive therapy, with hydroxyurea as the first-line agent.
- Current treatments do not improve survival or prevent progression to myelofibrosis or leukemia.
Conclusions:
- Persistent thrombocytosis necessitates a thorough diagnostic evaluation to rule out myeloproliferative neoplasms.
- Risk stratification using IPSET is crucial for guiding management decisions in essential thrombocythemia.
- While treatments manage symptoms and thrombosis risk, they do not alter the long-term prognosis of ET.
Related Concept Videos
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
01:24Disorders of Hemostasis
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
01:20Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
01:30Venous Thrombosis I: Introduction
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:20Extrinsic and Intrinsic Pathways of Hemostasis
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which forms a...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which forms a...